Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 6—June 2025

Dispatch

High Prevalence of Artemisinin-Resistant Plasmodium falciparum, Southeastern Sudan

Mariangela L’Episcopia, Albadawi A. Talha, Bakri Y.M. Nour, Ibrahim Mohamed Ahmed Sana, Emmanuelle Caspar, Lucas Thiebaut, Lucien Platon, Buze Chala, Laurence Ma, Lemu Golassa, Edvige Perrotti, Carlo Severini, and Didier Menard
Author affiliation: Istituto superiore di sanità, Rome, Italy (M. L’Episcopia, E. Perrotti, C. Severini); Jouf University, Sakaka, Saudi Arabia (A.A. Talha); University of Gezira, Wad Medani, Sudan (B.Y.M. Nour, I.M.A. Sana); University of Strasbourg, Strasbourg, France (E. Caspar, L. Thiebaut, L. Platon, D. Menard); Addis Ababa University, Addis Ababa, Ethiopia (B. Chala, L. Golassa); Institut Pasteur, Paris, France (L. Ma, D. Menard); Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France (D. Menard); Institut Universitaire de France, Paris (D. Menard)

Main Article

Table 1

Frequency of the Pfkelch13, Pfcrt, Pfmdr-1, dhfr, and dhps genotypes in blood samples collected in patients with Plasmodium falciparum malaria before artemisinin-based combination therapy from Al Jazirah and Al Qadarif, Sudan, 2017*

Gene Codon Amino acid No. (%) samples
p value
Al Jazirah Al Qadarif Total
No. samples
NA
NA
170
87
257
NA
Pfkelch13
Wilms tumor NA 123 (72.4) 69 (79.3) 192 (74.7) 0.01
494 Valine → Isoleucine 1 (0.6) 0 1 (0.4)
622 Arginine → Isoleucine 42 (24.7) 10 (11.5) 52 (20.2)
625 Glycine → Arginine 1 (0.6) 6 (6.9) 7 (2.7)
622/625 Arginine → Isoleucine / Glycine → Arginine 1 (0.6) 2 (2.3) 3 (1.2)
622/494 Arginine → Isoleucine / Valine → Isoleucine 1 (0.6) 0 1 (0.4)
494/658
Valine → Isoleucine / Lysine → Threonine
1 (0.6)
0
1 (0.4)
Pfcrt
72 Cysteine 170 (100) 87 (100) 257 (100) NA
Serine NA NA NA
74 Methionine 124 (73) 44 (51) 168 (65) 0.0004
Isoleucine 46 (27) 43 (49) 89 (35)
75 Asparagine 124 (73) 44 (51) 168 (65) 0.0004
Glutamic acid 46 (27) 43 (49) 89 (35)
76 Lysine 124 (73) 44 (51) 168 (65) 0.0004
Threonine 46 (27) 43 (49) 89 (35)
93 Threonine 170 (100) 86 (99) 256 (99.6) 0.2
Serine 0 1 (1) 1 (0.4)
356
Isoleucine 169 (99) 85 (98) 254 (98.8) 0.2
Threonine
1 (1)
2 (2)
3 (1.2)
Pfmdr-1
86 Asparagine 145 (85) 75 (86) 220 (86) 0.8
Tyrosine 25 (15) 12 (14) 37 (14)
184 Tyrosine 20 (12) 14 (16) 34 (13) 0.3
Phenylalanine 150 (88) 73 (84) 223 (87)
1034 Serine 139 (82) 70 (80) 209 (81) 0.8
Cysteine 31 (18) 17 (20) 48 (19)
1042 Asparagine 170 (100) 87 (100) 257 (100) NA
Aspartic acid NA NA NA
1246
Aspartic acid 170 (100) 87 (100) 257 (100) NA
Tyrosine
NA
NA
NA
dhfr
51 Asparagine 79 (46) 16 (18) 95 (37) <0.0001
Isoleucine 91 (54) 71 (82) 162 (63)
59 Cysteine 151 (90) 76 (87) 227 (89) 0.4
Arginine 16 (10) 11 (13) 27 (11)
108 Serine 72 (42) 22 (25) 94 (37) 0.007
Asparagine 98 (58) 65 (75) 163 (63)
164
Isoleucine 170 (100) 87 (100) 257 (100) NA
Leucine
NA
NA
NA
dhps 431 Isoleucine 170 (100) 87 (100) 257 (100) NA
Valine NA NA NA
436 Serine 167 (98) 83 (95) 250 (97) 0.2
Alanine 3 (2) 4 (5) 7 (3)
437 Alanine 30 (18) 35 (40) 65 (25) 0.0001
Glycine 140 (82) 52 (60) 192 (75)
540 Lysine (K) 162 (95) 72 (83) 234 (91) 0.0009
Glutamic acid 8 (5) 15 (17) 23 (9)
581 Alanine 170 (100) 87 (100) 257 (100) NA
Glycine NA NA NA
613 Alanine 169 (99) 86 (99) 255 (99) 0.6
Serine 1 (1) 1 (1) 2 (1)

*p values indicate the difference in percentages between sites. NA, not available. †Pfkelch13 622I/625R, 1 sample from Al Jazirah and 2 samples from Al Qadarif; Pfkelch13 494I/622I, 1 sample from Al Jazirah; Pfkelch13 494I/658T, 1 sample from Al Jazirah.

Main Article

Page created: April 25, 2025
Page updated: May 20, 2025
Page reviewed: May 20, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external